FOLFOX
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
FOLFOX
Jun 27, 2024, 09:01 |
Insight
Piotr Wysocki: Anti-inflammatory drugs improve outcomes of patients with early PIK3CA-mutated colorectal cancer
Piotr Wysocki recently posted on LinkedIn: "For many years, anti-inflammatory drugs, mainly aspirin and celecoxib, have…
Jun 8, 2024, 18:36 |
Dialogues
ASCO24 Updates: Introduction to the PanaMa Trial and its Objectives
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
May 15, 2024, 14:44 |
Blog
Maria Babak: Welcome to our May edition of Babak Monthly!
Maria Babak, Head of Drug Discovery Lab at City University of Hong Kong, shared a post…
Mar 23, 2024, 14:45 |
Insight
Article summaries by Erman Akkus: BMI and cancer prognosis and billiary tract cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X/Twitter: 1. ''BMI, weight…
Jan 22, 2024, 16:22 |
Insight
Krishan Jethwa: Rectal Cancer Tweetorial!!
Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic Rochester,shared on X: "Rectal Cancer…
Nov 4, 2023, 17:29 |
Blog
David Sebag: Delighted our letter about the PROSPECT rectal cancer trial
Quoting David Sebag-Montefiore, Director at Leeds Cancer Research Centre, on X/Twitter: “Delighted our letter about…
Nov 1, 2023, 18:31 |
Drugs
David Sebag-Montefiore: We strongly caution against the use of FOLFOX alone applied to the whole PROSPECT trial population
David Sebag-Montefiore shared on LinkedIn: "Delighted to see our letter published in the New England Journal…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube